Search - tctmd.com

Displaying 141 - 160 of 190

Sort: Relevancy | Date

News Conference News EuroPCR 2017

Big Questions for Bioresorbable Scaffolds: Experts and Innovators Debate

Michael O'Riordan

May 15, 2017

News Daily News

$2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor

Michael O'Riordan

May 12, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

Shelley Wood

March 10, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for February 2017

Shelley Wood

March 01, 2017

News Features

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

Shelley Wood

December 30, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular News and Features for 2016

Shelley Wood

December 29, 2016

News Daily News

Prior Atherosclerosis Ups the Risk of Dying After Acute MI

Michael O'Riordan

December 09, 2016

News Conference News AHA 2016

My Takeaways From AHA 2016: Too Late, Too Soon—Time Waits for No Trial

Shelley Wood

November 28, 2016

News Conference News AHA 2016

Impaired Coronary Flow Reserve May Represent Hidden Biological Risk for Women

L.A. McKeown

November 17, 2016

News Conference News AHA 2016

AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR

Shelley Wood

November 09, 2016

News Conference News TCT 2016

COLOR: PCI of Lipid-Rich Plaque Not Associated With Increased Risk of Adverse Events

Michael O'Riordan

November 01, 2016

Presentation TCT 2016

Are PCSK9 Inhibitors and Anti-inflammatory Therapies for Vulnerable Plaque Right Around the Corner?

Presenter: Gregg W. Stone, Ron Waksman, Sanjit S. Jolly

November 01, 2016

News Daily News

La AHA Facilita las Interacciones Farmacológicas entre Estatinas y Fármacos contra la Enfermedad Cardiovascular

Michael O'Riordan

October 18, 2016

News Daily News

AHA 提供他汀类药物和心血管药物药物相互作用指导

Michael O'Riordan

October 18, 2016

News Daily News

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

Michael O'Riordan

September 27, 2016

News Daily News

Evolocumab Modifies IVUS-Detected Coronary Atherosclerosis: Topline Results From GLAGOV

Michael O'Riordan

September 20, 2016

News Industry News

Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab)

September 20, 2016

News Daily News

太多主角：不同指南 CVD 风险评估存在混淆和不一致

Michael O'Riordan

September 16, 2016

News Daily News

Many Guidelines, Mixed Consensus: Different CVD Risk Guidelines Cause Confusion in Practice

Michael O'Riordan

September 16, 2016

Advertisement

Big Questions for Bioresorbable Scaffolds: Experts and Innovators Debate

$2 Billion Annual Price Tag for FOURIER-Eligible VA Patients on PCSK9 Inhibitor

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

TCTMD’s Top 10 Most Popular Stories for February 2017

Year in Review: Physicians Pick the Biggest News of 2016, in Interventional Cardiology and Beyond

TCTMD’s Top 10 Most Popular News and Features for 2016

Prior Atherosclerosis Ups the Risk of Dying After Acute MI

My Takeaways From AHA 2016: Too Late, Too Soon—Time Waits for No Trial

Impaired Coronary Flow Reserve May Represent Hidden Biological Risk for Women

AHA 2016: Back to the Bayou for Functional Tests, NSAIDs, and Intermediate-Risk TAVR

COLOR: PCI of Lipid-Rich Plaque Not Associated With Increased Risk of Adverse Events

Are PCSK9 Inhibitors and Anti-inflammatory Therapies for Vulnerable Plaque Right Around the Corner?

La AHA Facilita las Interacciones Farmacológicas entre Estatinas y Fármacos contra la Enfermedad Cardiovascular

AHA 提供他汀类药物和心血管药物药物相互作用指导

Lowering LDL With Statins and Other Selected Agents Should Be Focus of CVD Risk Reduction, Analysis Implies

Evolocumab Modifies IVUS-Detected Coronary Atherosclerosis: Topline Results From GLAGOV

Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab)

太多主角：不同指南 CVD 风险评估存在混淆和不一致

Many Guidelines, Mixed Consensus: Different CVD Risk Guidelines Cause Confusion in Practice

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content